

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement (MM/DD/YYYY)		3. Issuer Name and Ticker or Trading Symbol		
McDonald Richard T			12/7/2020		CLOROX CO /DE/ [CLX]		
(Last) (First) (Middle)			4. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
1221 BROADWAY			<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) SVP - Chief Product Supply Off /				
(Street)			5. If Amendment, Date Original Filed(MM/DD/YYYY)		6. Individual or Joint/Group Filing(Check Applicable Line)		
OAKLAND, CA 94612-1888					<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person		
(City) (State) (Zip)							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	7962.0000	D	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 4)	2. Date Exercisable and Expiration Date (MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	9/17/2015 (1)	9/17/2024	Common Stock	4210.0000	\$89.8200	D	
Stock Option (Right to Buy)	9/15/2016 (1)	9/15/2025	Common Stock	2920.0000	\$111.6000	D	
Stock Option (Right to Buy)	9/13/2017 (1)	9/13/2026	Common Stock	2800.0000	\$123.0900	D	
Stock Option (Right to Buy)	9/12/2018 (1)	9/12/2027	Common Stock	2150.0000	\$135.5700	D	
Stock Option (Right to Buy)	9/18/2019 (1)	9/18/2028	Common Stock	5600.0000	\$151.8500	D	
Stock Option (Right to Buy)	9/17/2020 (1)	9/17/2029	Common Stock	6868.0000	\$155.5400	D	
Stock Option (Right to Buy)	9/22/2021 (1)	9/22/2030	Common Stock	2625.0000	\$212.3800	D	

Explanation of Responses:

(1) Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date.

Remarks:

November 15, 2020

Securities and Exchange Commission
450 Fifth Street N.W.
Washington, DC 20549

Ladies and Gentlemen:

This letter authorizes the following representatives of The Clorox Company, acting singly, to execute and file with you on my behalf future Forms 3, 4 and 5 respecting my holdings of equity securities of The Clorox Company:

Angela Hilt, Vice President, Corporate Secretary & Deputy General Counsel Jinho Joo, Director of Legal
Cheryl Brice, Assistant Secretary and Corporate & Securities Specialist Tracy Tong, Senior Corporate Counsel

Sincerely,

/s/ Richard T. McDonald

Name: Richard T. McDonald

Title: SVP - Chief Product Supply Officer